Table 3.
Patient-reported usage of current acute treatment in insufficient responders/sufficient responders to acute treatment for migraine
| Insufficient responders (N = 227) | Sufficient responders (N = 311) | Total (N = 538) | |
|---|---|---|---|
| Time of administration of acute therapy, n (%)* | |||
| At first sign of a migraine | 49 (23.0) | 94 (31.1) | 143 (27.8) |
| When/after the pain starts | 164 (77.0) | 208 (68.9) | 372 (72.2) |
| Continue using currently prescribed acute medication, n (%)* | |||
| Definitely yes | 48 (21.6) | 132 (43.1) | 180 (34.1) |
| Probably yes | 121 (54.5) | 147 (48.0) | 268 (50.8) |
| Do not know | 43 (19.4) | 24 (7.8) | 67 (12.7) |
| Probably not | 10 (4.5) | 2 (0.7) | 12 (2.3) |
| Definitely not | 0 | 1 (0.3) | 1 (0.2) |
| Ever needs to take extra doses to relieve pain/migraine symptoms, n (%)* | 85 (41.1) | 52 (18.7) | 137 (28.2) |
| Number of times extra doses of a prescribed acute medication were taken for the last ten migraine attacks, mean ± SD*a | 3.34 ± 2.1 | 2.14 ± 1.9 | 2.89 ± 2.1 |
Reported data are number and percentage of patients, unless stated otherwise, with percentages calculated as proportion of non-missing data
*p < 0.05 between insufficient responders and sufficient responders. For categorical measures, chi-squared or Fisher’s exact test was used. For continuous measures, t-test was used
aAssessed in patients needing to take extra doses to control pain/migraine symptoms
SD standard deviation